CVS Just Broke Up With Its Own $78 Billion Mistake, and Wall Street Sent Flowers
By Dakota Jones
Desk: Economic, Business & Financial.
CVS Health says it plans to split into two publicly traded companies. Wall Street’s response? Not flowers. CVS shares fell more than 12% on November 4, the day the company announced the plan.
Meanwhile, the same company reported third-quarter 2026 revenues of $108.4 billion, up 5.4% from a year earlier, raised its full-year guidance, and still got punished. That’s the market for you: beat the quarter, raise the outlook, and get handed a 12% haircut anyway.
So what actually happened, why did Wall Street flinch, and should you care? Yes, you should. If you fill prescriptions, pay insurance premiums, or have ever stood in a CVS aisle at 2 a.m. wondering why there are nine cashiers and one open lane, this one’s aimed at you.
What happened: CVS plans to split in two
CVS announced on November 4 that it intends to create two independent, publicly traded companies. The separation is targeted for the first half of 2028, subject to approvals and other conditions. Until it happens, CVS says it will continue to operate as it does today.
The proposed companies would be:
- CVS Health: Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health.
- CVS Pharmacy: About 9,000 CVS pharmacies, mail pharmacy, MinuteClinic, including virtual care, and Health100 technology services.
Existing CVS shareholders are expected to own shares in both companies after the separation. The proposed transaction is intended to be tax-free for CVS and its shareholders, but the company says that outcome depends on conditions including regulatory filings, board approval and confirmation of the tax treatment.
That distinction matters: Aetna stays with the health-benefits and services business. The retail pharmacy chain is the piece slated to separate. So this is not CVS selling Aetna and walking away from the deal. It is a planned break-up of the integrated structure.
The $78 billion number: a big deal, not a booked loss
CVS completed its acquisition of Aetna in 2018. At the time, CVS said the transaction valued Aetna at about $70 billion; including assumed Aetna debt, the total transaction value was $78 billion.
The merger’s logic was easy to pitch: bring insurance, pharmacy benefits, drug services and local care closer together. CVS described a future of simpler access and better-connected care. In theory, more coordination could mean better service and lower costs.
Here’s where the sarcasm pays its rent, because the numbers in the Q3 release are genuinely good. Adjusted earnings per share hit $2.09, up from $1.60 a year ago. GAAP diluted EPS came in at $1.68, a swing from last year’s loss of $3.13 per share, which was dragged down by a $5.7 billion goodwill impairment charge. Cash flow from operations year to date: $15.3 billion. And CVS raised its full-year 2026 adjusted EPS guidance to at least $8.20, from a prior range of $7.90 to $8.10, while bumping its operating cash flow target to at least $15.5 billion from at least $11.5 billion.
That is a company firing on most of its cylinders. And the stock still fell more than 12% in a single session, per CNBC’s market coverage. Investors took one look at the breakup announcement and decided the road from here to the first half of 2028 has enough potholes to justify selling now and asking questions later.
The proposed separation is a sign that management sees more value in running the retail pharmacy business independently from the insurance-and-services group. Whether that undoes any of the original merger’s flaws is unknowable today. What is knowable: the market is not waiting around to find out.
Why it matters: focus is promising; execution is the test
The business case CVS is making is straightforward. Separate companies could have clearer priorities, dedicated leadership and capital structures tailored to their operations. CVS says each company would be able to focus on its own customers and invest in its own strategy.
There may also be a practical reason to draw a sharper boundary. A pharmacy benefit manager, or PBM, manages prescription drug benefits for health plans and employers. When one company owns the PBM, the insurer and the pharmacies, everyone from Congress to your aunt with a copay complaint asks whose incentives are doing the driving. Splitting the retail business from the health-benefits operation does not erase those questions, but it does change the structure that has been under fire for years.
CVS says the split will be tax-free to shareholders, that both companies are expected to carry solid investment-grade ratings, and that each will generate strong free cash flow and pay an attractive dividend. David Joyner, currently chairman and CEO, will lead the healthcare solutions company. Prem Shah, currently group president, will run CVS Pharmacy. Goldman Sachs and Consello are advising; Wachtell, Lipton, Rosen & Katz is handling legal.
That is the promise. The hard part is making the new arrangement work. Investors will want details on debt allocation, separation costs, the commercial contracts that will tie the two companies together, and how much coordination actually survives the breakup. A corporate split can simplify an organization chart. It cannot, on its own, fix underlying economics. And make no mistake, there will be separation costs. There are always separation costs. Corporate divorces are priced like celebrity weddings.
For customers and patients, CVS says the transition will not interrupt access to medicines, care, benefits or services. Translation: your pharmacist stays your pharmacist. The plan is years away and still conditional, so file this under “believe it when the Form 10 clears.”
What the market reaction says, and doesn’t say
The share-price drop is a clear signal that investors did not greet the announcement with uncomplicated enthusiasm. It is not a verdict on what the separated companies will be worth in 2028. Markets hate uncertainty more than they hate bad news, and a two-year corporate breakup plan is basically an uncertainty subscription service with no cancel button.
Also worth noting: it was a busy tape. AI-linked infrastructure stocks slid on election-driven questions about the data center buildout, defense names like Lockheed Martin fell 6%, and Trump Media dropped 11% on the midterm results. CVS’s 12% drop landed in a market that was already in a mood. The title says Wall Street sent flowers. The tape suggests it sent questions instead.
For more coverage, visit LD3 Productions’ Economic, Business & Financial news desk.
FAQ
Has CVS sold Aetna?
No. Under the announced plan, Aetna would remain in the CVS Health company alongside Caremark and other health businesses.
Is the separation complete?
No. CVS intends to complete it in the first half of 2028, subject to customary conditions and approvals.
Will current shareholders own both companies?
That is the plan CVS announced. Shareholders are expected to own shares in both after the separation.
Verdict: the structure is changing; the proof comes later
CVS is not reversing its Aetna acquisition by selling the insurer. It is proposing to separate the retail pharmacy chain from the broader health-benefits and services operation that includes Aetna.
That is a consequential change in strategy. It may give each business more focus. It may also bring costs and new coordination challenges. The $78 billion figure describes the 2018 transaction’s total value, including assumed debt, not a loss CVS has admitted or a sum shareholders are about to get back.
The verdict is simple: CVS is betting that two focused companies can do better than one integrated giant. The announcement starts that test. It does not finish it.